European Medicines Agency’s Pharmacovigilance Risk Assessment Committee Recommends Suspending Marketing Authorizations for Infusion Solutions Containing Hydroxyethyl Starch
On June 14, 2013, following a review of the available evidence, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the benefits of... Read More
